Strata Critical Medical, Inc. shareholders approved Advisory approval of named executive officer compensation at the 2026-05-28 meeting.
“For Against Abstain Broker Non-Votes 38,497,962 8,022,682 35,679 12,687,496”
Strata Critical Medical, Inc. — fact timeline
Source-grounded facts extracted from Strata Critical Medical, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Strata Critical Medical, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year 2026 at the 2026-05-28 meeting.
“For Against Abstain 58,946,832 65,815 231,172”
Strata Critical Medical, Inc. shareholders approved Election of two Class II directors to hold office until the 2029 annual meeting at the 2026-05-28 meeting.
“For Withhold Broker Non-Votes William A. Heyburn 46,050,902 505,421 12,687,496 Andrew Lauck 39,525,159 7,031,164 12,687,496”
Strata Critical Medical, Inc. updated its first quarter ended March 31, 2026 guidance (reaffirmed).
“On May 6, 2026, Strata Critical Medical, Inc. (“Strata”) issued a press release announcing its financial results for the first quarter ended March 31, 2026.”
Strata Critical Medical, Inc. entered into Credit Agreement with JPMorgan Chase Bank, N.A., as administrative agent, the other Loan Parties thereto, and the Lenders thereto valued at up to $30.0 million (effective 2026-01-30).
“On January 30, 2026 (the “Closing Date”), Strata Critical Medical, Inc. (the “Company”), Strata Critical, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“Critical”), Trinity Air Medical, LLC, an Arizona limited liability company and wholly owned subsidiary of Critical (“Trinity Air”), Keystone Perfusion Services, LLC, a Pennsylvania limited liability company and wholly owned subsidiary of Critical (“Keystone”; together with Trinity Air and any other person that becomes party thereto as a Borrower, collectively, the “Borrowers”), entered into a Credit Agreement (the “Credit Agreement”) among the Borrowers, the Company and Critical, JPMorgan Chase Bank, N.A., as administrative agent (the “Administrative Agent”), the other Loan Parties thereto, and the Lenders thereto.”
Strata Critical Medical, Inc. completed an acquisition involving Keystone Perfusion Services, LLC (closed 2025-09-16).
“the completion of the acquisition of Keystone Perfusion Services, LLC ("Keystone") by way of acquiring all the issued and outstanding equity interests of Keystone”
Strata Critical Medical, Inc. completed an acquisition involving Keystone Perfusion Services, LLC, LRV Holdco, Inc. for $124 million, subject to adjustment, payable eighty percent in cash and twenty percent in shares of the Company’s common stock (closed 2025-09-16).
““Closing”) occurred on September 16, 2025. The aggregate consideration (including contingent consideration) payable by Buyer in connection with the Acquisition consists of (a) $124 million, subject to adjustment as set forth in the Purchase Agreement, payable eighty percent in cash and twenty percent in shares of the Company’s common stock, par value $0.0001 per”
Strata Critical Medical, Inc.: Adopted amended bylaws reflecting name change and other governance revisions (effective 2025-08-28).
“Additionally, on August 28, 2025, the Board approved an amendment to the Company’s Amended and Restated Bylaws (as so amended and restated, the “Amended Bylaws”).”
Strata Critical Medical, Inc.: Amended charter to change company name to Strata Critical Medical, Inc (effective 2025-08-28).
“On August 28, 2025, Board approved an amendment to the Company’s Second Amended Restated Certificate of Incorporation, as amended (the “Charter”), to change the Company’s name to Strata Critical Medical, Inc.”
Strata Critical Medical, Inc. completed a disposition involving Joby Aero, Inc. for approximately $76.0 million (closed 2025-08-29).
“of Joby Aviation. The purchase price received by the Company upon the consummation of the transactions contemplated by the Purchase Agreement (the “Closing”) was approximately $76.0 million (assuming the closing price per share of $14.27 of Joby Aviation’s common stock as of August 28, 2025), after giving effect to pre-Closing adjustments and indemnity holdbacks”
Strata Critical Medical, Inc. shareholders approved Ratification of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-02 meeting.
“The Company’s stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Strata Critical Medical, Inc. shareholders approved Election of two Class III directors at the 2024-05-02 meeting.
“On May 2, 2024, Blade Air Mobility, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”).”
Strata Critical Medical, Inc. updated its the first quarter ended March 31, 2024 guidance (reaffirmed).
“On May 7, 2024, Blade Air Mobility, Inc. (“Blade”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.”
Strata Critical Medical, Inc. engaged Deloitte & Touche LLP as its auditor.
“On March 20, 2024, the Audit Committee approved the appointment of Deloitte & Touche LLP ("Deloitte") as its new independent registered public accounting firm for the fiscal year ending December 31, 2024, subject to execution of an engagement letter.”
Strata Critical Medical, Inc. dismissed Marcum LLP as its auditor.
“On March 19, 2024, the Audit Committee of the Board of Directors (the "Audit Committee") of Blade Air Mobility, Inc., a Delaware corporation (the "Company") dismissed Marcum LLP ("Marcum") as the Company's independent registered public accounting firm.”
Strata Critical Medical, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $47,478, net income $(33,941). Guidance initiated.
“2023. GAAP FINANCIAL RESULTS (in thousands except percentages, unaudited) Three Months Ended December 31, Year Ended December 31, 2023 2022 % Change 2023 2022 % Change Revenue $ 47,478 $ 38,135 24.5 % $ 225,180 $ 146,120 54.1 % Cost of revenue 38,468 33,160 16.0 % 183,058 123,845 47.8 % Software development 988 1,622 (39.1) % 4,627 5,545 (16.6) % General and”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.